JAMA Network
About The Study: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly used for postpartum weight loss since the introduction of semaglutide for weight loss in late 2022. Most users were overweight prior to pregnancy and only 23% had a documented diabetes diagnosis, suggesting that the primary indication for use was weight reduction.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
